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osting by EAbstract Estrogens, and particularly glucuronides such as ethinylestradiol (EE), have been shown to
cause cholestasis in animal studies, by reducing bile acid uptake by hepatocytes. The aim of the present
article is to investigate anticholestatic activity of the ethanolic extract of the aerial parts of Jasoniamon-
tana against liver cholestasis induced by EE in adult female rats in an attempt to understand its mech-
anism of action, which may pave the way for possible therapeutic applications. Subcutaneous
administration of 100 lg/kg b.w. ethinylestradiol to rats induced hepatocellular cholestasis with a sig-
niﬁcant decrease in serum cholesterol, bile acids and bilirubin levels as well as in hepatic superoxide
dismutase (SOD), glutathione peroxidase (GPx), glutathione reductase (GR) activities and hepatic
total, protein-bound and non-protein sulfhydryl groups. Also, treatment with EE produced signiﬁcant
increase in serum Pi-glutathione-s-transferase (Pi-GST), gamma glutamyl transpeptidase (c-GT) and
alpha-glutathione-s-transferase (a-GST) activities as well as serum nitric oxide (NO) and tumor necro-
sis factor alpha (TNF-a) level and hepatic malondialdehyde (MDA) level as compare to control group.
Oral administrationof the aerial parts of ethanolic extract at a concentrationof 150 mg/kg b.w. daily to
rats treatedwith EE for 15 days showed a signiﬁcant protection against-induced decrease in serum cho-
lesterol, bile acids and bilirubin levels. The treatment also resulted in a signiﬁcant increase in hepatic
SOD, GPx and GR activities as well as hepatic total, protein-bound and non-protein sulfhydryl
groups. In addition, the extract could inhibit serum Pi-GST, c-GT and a-GST activities as well as
reduce serumTNF-a, NO and hepaticMDA as compare to ethinylestradiol treated rats. High content
of ﬂavonoids and phenolic compounds was found in ethanolic extract, which may be responsible for
free radical activity. The results clearly suggest that the aerial parts of J.montana extractmay effectively
normalize the impaired antioxidant status in ethinylestradiol (EE)-cholestatic model. Thus the extract
may have a therapeutic value in drug-induced biliary cholestasis as well as in hormonal therapy.
ª 2009 King Saud University. All rights reserved.hotmail.com (M.A. Hussein).
ity. All rights reserved. Peer-
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lsevier1. Introduction
Hepatocellular cholestasis is a known complication of chronic
estrogen administration either in oral contraceptives postmen-
opausal replacement therapy.
Moreover, estrogens have been also involved in the
pathogenesis of cholestasis in the last trimester of pregnancy
(Kreek, 1987). Experimental cholestasis produced by estrogen
28 M.A. Hussein, S.M. Abdel-Gawadadministration, mainly ethinylestradiol, in rats is widely used
as an investigated model of hepatocellular cholestasis (Bossard
et al., 1993). The mechanism by which EE induces cholestasis
is still unclear although interference with bile salt-independent
bile ﬂow (Guevas et al., 2001) and reduced capacity of hepato-
cytes to excrete organic anions and cholephilic compounds has
been suggested (Alvaro et al., 1997). EE treatment is also asso-
ciated with several hepatocellular changes, which include de-
creased plasma membrane ﬂuidity, decreased Na+–K+-
ATPase (Simon et al., 1996) and substantial decreased in the
volume density of sinusoidal microvilli and the sinusoidal plas-
ma membrane surface density (Hornstein et al., 1992). Chronic
cholestatic liver diseases, including primary biliary cirrhosis,
extrahepatic biliary arresia, idiopathic adulthood ductopenia,
primary sclerosing cholangitis, idiopathic neonatal hepatitis,
Byler’s disease and arteriohepatic dysplasia, are leading indica-
tions for liver transplantation (Kim et al., 2000).
The endogenous antioxidant enzymes (e.g. SOD, CAT,
GSH and GPx) are responsible for the detoxiﬁcation of delete-
rious oxygen radicals (Jacob, 1995). Many plant extracts and
plant products have been shown to have signiﬁcant antioxidant
activity (Scartezzini and Speroni, 2002), which may be an
important property of medicinal plants associated with the
treatment of several ill fated diseases including cholestasis.
Thus, herbal plants are considered as useful means to prevent
and/or ameliorate certain disorders, such as diabetes, athero-
sclerosis and other complications (Scartezzini and Speroni,
2002). Plant-derived poly-phenols minimize cholestasis-in-
duced liver injury (Zhong et al., 2003). Therefore, new strate-
gies to prevent cholestasis-induced liver injury and ﬁbrosis is
needed. Previous studies suggest that oxidative stress occurs
during cholestasis and likely plays a role in cholestasis-induced
liver injury (Alptekin et al., 1997; Pastor et al., 1997; Sokol
et al., 1995). Accordingly, antioxidant therapy represents a po-
tential strategy to prevent liver injury and ﬁbrosis. Poly-phe-
nols exist in many plants and are especially abundant in
Jasonia montana (Tawfeq et al., 2005), whose dried leaves are
used as antioxidant. J. montana and polyphenol-enriched plant
extracts have no known toxicity. Thus poly-phenols from J.
montana and possibly other plant sources represent a promising
potential species (Hussein, 2008). These poly-phenols are more
potent antioxidants than vitamins C and E (Zhao et al., 1989).
Polyphenol rich extracts fromJ. montana inhibit lipid peroxida-
tion in experimental animals (Hussein, 2008). Not surprisingly,
plants such as J. montana contain high levels of poly-phenols
(Tawfeq et al., 2005), which are excellent scavengers of reactive
and represent a promising anticholestatic effect.
The plant J. montana occurs in the Mediterranean and adja-
cent areas (Merxmuller et al., 1977), including the Sinai Penin-
sula (Scartezzini and Speroni, 2002). The herb has a strong
aromatic odor and is used in traditional medicine for diarrhea,
stomach ache and chest diseases (Tackholm, 1974). A literature
survey indicated that some mono and sesquiterpenes (Tack-
holm, 1969; Ahmed and Jakupovic, 1990; Eid et al., 1987;
Ahmed et al., 1988), ﬂavonoids (Ahmed, 1991) and essential
oils (Ahmed et al., 1989) have been reported from the plant.
The different extracts of the plant were also screened for hypo-
glycemic and antidiabetic activities at concentration of 200 mg/
kg body weight of each extract (petroleum ether, chloroform
and ethanol) suspended in distilled water (Tawfeq et al.,
2005). Recently, (Hussein, 2008) studied the antioxidant activ-
ities of the ethanolic and aqueous extracts of the aerial parts ofJ. montana in streptozotocin-induced diabetic rats and showed
a signiﬁcant decrease in fasting blood glucose, hepatic and renal
thiobarbituric acid reactive substances and hydroperoxides.
In vitro tests have been conducted with J. montana to
determine for example, its hypoglycemic and antioxidant
activity (Hussein, 2008). But there are no reports of the effect
of J. montana on liver cholestasis.
The present study was undertaken to investigate the
hepatoprotective activity of J. montana extract in the form of
ethanolic formulation to alleviate the adverse effects of ethiny-
lestradiol on liver.2. Materials and methods
2.1. Chemicals
– Ethinylestradiol (EE) was obtained from Sigma Chemical
Co. (St. Louis, MO, USA).
– Propylene glycol was produced by Panreac Quimica, SA,
Barcelona, Spain.2.2. Plant material
Fresh aerial parts of J. montana were collected from the Sinai
Peninsula.
2.3. Preparation of ethanolic extract
Air-dried aerial parts of the plant (1.5 kg) was crushed to
coarse powder and extracted exhaustively in a Soxhlet with
95% ethanol. The extract was concentrated under reduced
pressure to yield viscous mass. The ethanolic extract was kept
in airtight containers in a deep freeze maintained at 4 C until
the time of further use.
2.4. Phytochemical screening
A phytochemical analysis of aerial parts of J. montana was
conducted for the detection of alkaloids, cardiac glycosides,
ﬂavonoids, tannins, anthraquinones, saponins, volatile oil,
coumarins and triterpenes (Hammerschmidt et al., 1993).
2.5. Animals
Adult female albino rats weighing around 180–200 g, at the
age of 10 weeks were purchased from Faculty of Veterinary
Medicine, Cairo University. They were acclimatized to animal
house conditions. Animals were provided with standard diet
and water ad libitum. Rats were kept under constant environ-
mental condition and observed daily throughout the experi-
mental work.
2.6. Experimental set-up
The animals were divided into ﬁve groups with six animals in
each.
Group I: normal control (was given similar volume of pro-
pylene glycol).
Group II: was treated with ethanolic extract (150 mg/kg
b.w.) suspended in propylene glycol orally for 15 days (Farns-
worth, 1966).
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propylene glycol) in a single daily dose for the last 5 days of the
experimental period (Rodriguez et al., 1992).
Group IV: was pretreated with ethanolic extract (150 mg/kg
b.w) alone for 10 days then received both ethanolic extract and
EE (100 lg/kg b.w.) for other 5 days (prophylactic I).
Group V: was simultaneously given ethanolic extract
(150 mg/kg b.w) and EE (100 lg/kg b.w.) for 5 days followed
by ethanolic extract alone for other 10 days (prophylactic II).
2.7. Sample collection and homogenate preparation
Fasting blood samples were collected, 24 h after the last treat-
ments, from the retroorbital plexus (Schermer, 1967) under
anaesthesia using diethylether. The blood samples were left
to clot and the sera were separated using cooling centrifuge
and stored at 20 C until analysis. After blood collection,
all animals were rapidly killed and liver tissues were dissected
and immediately homogenized in phosphate buffer (pH 7.4) to
give 20% w/v homogenate (Lin et al., 1998). The homogenate
was centrifuged at 1700 rpm and 4 C for 10 min and the
supernatant (20%) was used for determination of lipid perox-
ides, glutathione reductase (GR) activity, the contents of the
total (T-SH), of the protein-bound (PB-SH) and of the non-
protein (NP-SH) sulfhydryl groups and it was further diluted
with phosphate buffer solution to give 2% and 0.5% dilutions
for determination of glutathione peroxidase and superoxide
dismutase, respectively.
2.8. Biochemical assays
Serum cholesterol, bile acids and bilirubin were done by the
methods described by Rishmond (1973), Mashige et al.
(1981) and Sherlock (1951), respectively. Quantitative estima-
tion of serum (Pi-GST) was carried out by enzyme linked
immunosorbent assay (ELISA) according to Platz et al.
(1997) method. The activity of (c-GT) was estimated by the
method of Szasz (1969). Quantitative estimation of serum (a-
GST) was carried out by enzyme linked immunosorbent assay
(ELISA) according to Flendrig et al. (1999). Quantitative
determination of tumor necrosis factor-alpha (TNF-a) was
done by ELISA according to the method of Corti et al.
(1992). Serum nitrate concentration as a stable end product
of nitric oxide was estimated by the Griess reaction after quan-
titative conversion of nitrate to nitrite by nitrate reductase
according to the method of Moshage et al. (1995). Lipid perox-
idation in liver homogenate was estimated by measurement of
malondialdehyde (MDA) by spectrophotometer method (Est-Table 1 Effect of ethanolic extract of J. montana on serum cholest
Groups Cholesterol (mg/100 ml)
Normal control 97.34 ± 4.2
Ethanolic extract 150 mg/kg b.w. 82.6 ± 3.5**
Ethinylestradiol (EE) 100 lg/kg b.w. 46.7 ± 2.5**
Ethanolic extract + (EE) (prophylactic I) 61.9 ± 4.7*
(EE) + ethanolic extract (prophylactic II) 77.4 ± 5.1**
Ethanolic extract and ethinylestradiol (EE) treated rats were compared wi
with ethinylestradiol (EE) treated rats.
* Values are given as mean ± SD for groups of six animals each. Values
** Values are statistically signiﬁcant at P< 0.05.erbauer et al., 1991). The level of lipid peroxides was expressed
as nmol malonaldehyde/mg protein. The protein content of li-
ver tissue was measured by applying the method of Lowry
et al. (1951). Superoxide dismutase activity in liver homoge-
nate was assayed by red formazan dye reduction produced
(Suttle, 1986) using 50 ll diluted homogenate. Liver glutathi-
one peroxidase activity was determined using reduced glutathi-
one and cumene hydroperoxide as substrate using 20 ll diluted
homogenate by the modiﬁed method of Paglia and Valentine
(1967). The speciﬁc activities of superoxide dismutase and
glutathione peroxidase were expressed as units of activity/mg
protein. The glutathione reductase activity was measured
according to the method of Horn (1965); whereas the sulfhy-
dryl groups were recorded according to the method of Sedlak
and Lindsay (1968).
2.9. Statistical analysis
All the grouped data were statistically evaluated with SPSS/7.5
software. Hypothesis testing methods included one way analy-
sis of variance (ANOVA) followed by least signiﬁcant differ-
ence (LSD) test. P-values of less than 0.01 were considered
to indicate statistical signiﬁcance. All the results were ex-
pressed as mean ± SD for six separate determinations.
3. Results
Table 1 shows the speciﬁc cholestatic parameters among the
different groups. Ethinylestradiol (EE) administration for
5 days resulted in signiﬁcant decrease (p< 0.01) in serum cho-
lesterol, bile acids and bilirubin levels by 52.02%, 47.06% and
38.38%, respectively with concomitant increase in the activity
of ALP by 68.4% as compare to control group. These data
indicate that under the inﬂuence of ethanolic extract of J. mon-
tana a statistically signiﬁcant increase in serum cholesterol
(p< 0.01), bile acids and bilirubin levels (p< 0.05) by
32.55%, 14.8% and 29.5%, respectively with concomitant de-
crease in the activity of ALP (p< 0.01) by 31.1% in the group
of rats continuously treated with ethanolic extract before EE
injection as compare to EE-treated group. A signiﬁcant in-
crease in serum cholesterol (p< 0.05), bile acids and bilirubin
levels (p< 0.05) were observed in the group of rats continu-
ously treated with ethanolic extract after EE injection by
65.74%, 40.74% and 37.71%, respectively with concomitant
decrease in the activity of ALP (p< 0.05) by 21.1% as com-
pared to EE-treated group. The protective effect of extract
was more obvious in case of simultaneous administration of
EE and ethanolic extract (group 5).atic indices in rats treated with ethinylestradiol (EE).
Bile acids (lmol/L) Bilirubin (mg/100 ml) ALP (U/L)
5.1 ± 0.52 0.99 ± 0.045 210.17 ± 13.62
4.5 ± 0.09** 0.87 ± 0.034** 193.56 ± 8.43
2.7 ± 0.037** 0.61 ± 0.021** 354.11 ± 20.47**
3.1 ± 0.156* 0.79 ± 0.017* 243.92 ± 16.88*
3.81 ± 0.22** 0.84 ± 0.025** 279.16 ± 10.52**
th normal control rats. Experimental groups (4 and 5) were compared
are statistically signiﬁcant at P< 0.01.
Table 2 Effect of ethanolic extract of J. montana on serum Pi-glutathione-s-transferase (Pi-GST), gamma glutamyl transpeptidase (c-
GT) and alpha glutathione-s-transferase (a-GST) activity in rats treated with ethinylestradiol (EE).
Groups Pi-GST (lg/L) c-GT (U/L) a-GST (lg/L) ALT (U/L)
Normal control 16.41 ± 2.1 9.2 ± 1.32 181.67 ± 5.8 42.05 ± 3.76
Ethanolic extract 150 mg/kg b.w. 15.7 ± 2.9** 8.1 ± 1.49** 174.2 ± 7.1** 34.22 ± 4.08**
Ethinylestradiol (EE) 100 lg/kg b.w. 30.9 ± 3.7** 14.7 ± 3.89** 254.7 ± 10.4** 59.71 ± 5.11**
Ethanolic extract + (EE) (prophylactic I) 18.36 ± 2.1* 10.8 ± 2.15* 190.3 ± 6.9* 39.57 ± 2.94*
(EE) + ethanolic extract (prophylactic II) 23.11 ± 3.4** 12.3 ± 0.82** 211.6 ± 8.3** 45.31 ± 3.68**
Ethanolic extract and ethinylestradiol (EE) treated rats were compared with normal control rats. Experimental groups (4 and 5) were compared
with ethinylestradiol (EE) treated rats.
* Values are given as mean ± SD for groups of six animals each. Values are statistically signiﬁcant at P< 0.01.
** Values are statistically signiﬁcant at P< 0.05.
Table 3 Effect of ethanolic extract of J. montana on serum tumor necrosis factor alpha (TNF-a), serum nitric oxide (NO) and liver
malondialdehyde (MDA) level in rats treated with ethinylestradiol (EE).
Groups Serum TNF-a (pg/ml) Serum NO (lmol/L) Liver MDA (nmol/mg protein)
Normal control 73.6 ± 3.1 41.7 ± 4.9 37.6 ± 4.2
Ethanolic extract 150 mg/kg b.w. 49.7 ± 4.6** 34.6 ± 3.8** 24.9 ± 2.19**
Ethinylestradiol (EE) 100 lg/kg b.w. 97.8 ± 5.1** 59.3 ± 4.3** 64.1 ± 3.6**
Ethanolic extract + (EE) (prophylactic I) 67.4 ± 3.7* 39.6 ± 5.1* 45.07 ± 4.1*
(EE) + ethanolic extract (prophylactic II) 79.6 ± 5.3** 41.8 ± 3.4** 58.7 ± 3.9**
Ethanolic extract and ethinylestradiol (EE) treated rats were compared with normal control rats. Experimental groups (4 and 5) were compared
with ethinylestradiol (EE) treated rats.
* Values are given as mean ± SD for groups of six animals each. Values are statistically signiﬁcant at P< 0.01.
** Values are statistically signiﬁcant at P< 0.05.
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on serum activity of Pi-GST, c-GT, a-GST and ALT levels.
Serum activity of Pi-GST, c-GT, a-GST and ALT levels in-
creased signiﬁcantly (p< 0.05) in EE injected group by
88.3%, 59.78%, 40.2% and 41.9%, respectively as compared
to control group. Serum activity of Pi-GST, c-GT, a-GST
and ALT levels (p< 0.01) were signiﬁcantly decreased by
40.59%, 26.53%, 25.28% and 33.7%, respectively in rats trea-
ted with ethanolic extract of J. montana before EE injection, as
compared to EE-treated group. A signiﬁcant decrease in serum
activity of Pi-GST, c-GT, a-GST and ALT levels (p< 0.05)
were observed in the group of rats continuously treated with
ethanolic extract after EE injection by 25.21%, 16.33%,
16.92% and 24.1%, respectively as compared to EE-treated
group. The protective effect of extract was more obvious in
case of simultaneous administration of ethanolic extract and
EE (group 4).
Table 3 shows that signiﬁcantly increased (p< 0.01) in ser-
um TNF-a, serum NO and hepatic malondialdehyde in EE-
treated group by 32.88%, 42.2% and 70.48%, respectively as
compared to control group. A signiﬁcant decrease in serum
TNF-a, serum NO and hepatic malondialdehyde levels
(p< 0.01) were observed in the group of rats treated with eth-
anolic extract of J. montana before EE injection by 31.08%,
33.2% and 29.69%, respectively as compared to EE-treated
group. In the group of rats continuously treated with ethanolic
extract after EE injection both serum TNF-a, NO and hepatic
malondialdehyde levels decreased signiﬁcantly (p< 0.05) by
18.6%, 29.5% and 8.42%, respectively as compared to EE-
treated group. The effect was more pronounced in case of
simultaneous administration of extract before EE injection(group 4) compared to administration of extract after EE injec-
tion (group 5).
Table 4 showed signiﬁcant decreased (p< 0.05) in hepatic
SOD, GPx and GR (NADPH-dependent GR and NADH-
dependent GR) activities upon EE injection by 29.6%,
30.53%, 34.35% and 24.39%, respectively as compared to
the control group. A signiﬁcant decrease (p< 0.01) in hepatic
SOD, GPx and GR (NADPH-dependent GR and NADH-
dependent GR) activities were observed in the group of rats
treated with ethanolic extract ofJ. montana before EE injection
by 44.67%, 86.81%, 39.07% and 48.39%, respectively as com-
pared to EE-treated group. In the group of rats continuously
treated with ethanolic extract after EE injection both hepatic
SOD, GPx and GR (NADPH-dependent GR and NADH-
dependent GR) activities decreased signiﬁcantly (p< 0.05)
by 26.23%, 31.87%, 19.21% and 29.03%), respectively as
compared to EE-treated group. The protective effect of extract
was more obvious in case of simultaneous administration of
ethanolic extract and EE (group 4).
Table 5 shows signiﬁcant decreased (p< 0.05) in hepatic
total, protein-bound and non-protein sulfhydryl groups upon
EE injection by 21.72%, 19.72% and 33.06%, respectively as
compared to the control group. A signiﬁcant increase
(p< 0.01) in hepatic total, protein-bound and non-protein
sulfhydryl groups were observed in the group of rats treated
with ethanolic extract of J. montana before EE injection by
25.33%, 17.40% and 80.66%, respectively as compared to
EE-treated group. In the group of rats continuously treated
with ethanolic extract after EE injection both hepatic total,
protein-bound and non-protein sulfhydryl groups increase
signiﬁcantly (p< 0.05) by 16.75%, 12.98% and 42.39%,
Table 4 Effect of ethanolic extract of J. montana on liver superoxide dismutase (SOD), glutathione peroxidase (GPx) and glutathione
reductase (GR) activity in rats treated with ethinylestradiol (EE).
Groups SOD (pg/ml) GPx (lmol/L) GR (nmol/mg protein)
NADPH-dependent GR NADH-dependent GR
Normal control 118.6 ± 7.3 1.31 ± 0.02 2.3 ± 0.17 0.41 ± 0.03
Ethanolic extract 150 mg/kg b.w. 140 ± 9.1** 1.9 ± 0.01** 2.9 ± 0.09** 0.65 ± 0.02**
Ethinylestradiol (EE) 100 lg/kg b.w. 83.5 ± 6.4** 0.91 ± 0.04** 1.51 ± 0.18** 0.31 ± 0.01**
Ethanolic extract + (EE) (prophylactic I) 120.8 ± 5.3* 1.7 ± 0.02* 2.1 ± 0.16* 0.46 ± 0.02*
(EE) + ethanolic extract (prophylactic II) 105.4 ± 6.1** 1.2 ± 0.01** 1.8 ± 0.12** 0.40 ± 0.01**
Ethanolic extract and ethinylestradiol (EE) treated rats were compared with normal control rats. Experimental groups (4 and 5) were compared
with ethinylestradiol (EE) treated rats.
* Values are given as mean ± SD for groups of six animals each. Values are statistically signiﬁcant at P< 0.01.
** Values are statistically signiﬁcant at P< 0.05.
Table 5 Effect of ethanolic extract of J. montana on liver content of total, protein-bound and non-protein SH groups in rats treated
with ethinylestradiol (EE).
Groups Liver total-SH (nmol/mg protein) Liver PB-SH (nmol/mg protein) Liver NP-SH (nmol/mg protein)
Normal control 241.7 ± 10.6 205.4 ± 7.8 36.3 ± 3.9
Ethanolic extract 150 mg/kg b.w. 279.3 ± 8.2** 221.7 ± 9.1** 57.6 ± 4.5**
Ethinylestradiol (EE) 100 lg/kg b.w. 189.2 ± 7.5** 164.9 ± 7.7** 24.3 ± 2.7**
Ethanolic extract + (EE) (prophylactic I) 237.5 ± 9.3* 193.6 ± 8.1* 43.9 ± 3.3*
(EE) + ethanolic extract (prophylactic II) 220.9 ± 8.7** 186.3 ± 6.4** 34.6 ± 4.1**
Ethanolic extract and ethinylestradiol (EE) treated rats were compared with normal control rats. Experimental groups (4 and 5) were compared
with ethinylestradiol (EE) treated rats.
* Values are given as mean ± SD for groups of six animals each. Values are statistically signiﬁcant at P< 0.01.
** Values are statistically signiﬁcant at P< 0.05.
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effect of extract was more obvious in case of simultaneous
administration of ethanolic extract and EE (group 4).
4. Discussion
Cholestasis is an obstruction to bile ﬂow and can be induced
by drugs and other chemical e.g. erythromycin (Bachman
et al., 1994). This type of liver damage is usually acute and is
less common than fatty liver and necrosis (Plaa, 1993). The
cholestatic agents appear to act through several mechanisms.
Reduction of biliary excretory activity of the canalicular mem-
brane appears to be the predominant mechanism for cholesta-
sis (Bailic et al., 1994). Prolonged blockade of bile duct can
cause decreased elimination of conjugated bilirubin and an in-
crease in conjugated level in plasma, a symptom diagnostic for
obstructive jaundice (Cotran et al., 1999). Ethinylestradiol was
reported to decrease serum cholesterol level which is accompa-
nied with an increase in hepatic cholesterol level (Nikitin et al.,
1986). EE stimulates low density lipoprotein receptor activity
and increases the binding of lipoproteins to liver plasma mem-
brane (Bertolotti and Spady, 1996). Also, EE causes an in-
crease in hepatic catabolism of low density lipoprotein (Chao
et al., 1979). Both mechanism lead to marked hypercholester-
olemia observed after EE administration. In addition, EE has
been reported to stimulate the activity of the hepatic concen-
tration of cholesterol esters (Davis et al., 1978). The increase
in the hepatic content of cholesterol esters after EE administra-
tion has been regarded as being the basis of high microviscos-
ity of liver plasma membrane particularly at the basolateraldomain (Rosario et al., 1988). EE could decrease serum bile
acids level through the inhibition of cholesterol-7a-hydroxy-
lase activity which is responsible for bile acids synthesis (Davis
et al., 1986). Also, the decrease in bile ﬂow due to cholesterol
precipitation may be responsible for the reduced level of bile
acids in serum after EE administration (Portincasa et al.,
1997). Pi-glutathione-s-transferase (Pi-GST) is another speciﬁc
marker for hepatocellular cholestasis since it is located in the
cytoplasm of intrahepatic bile duct cells (Campbell et al.,
1991). The present results show marked increased in serum
Pi-GST, c-GT and ALP activity in EE-treated group. The ob-
tained data in the present study demonstrated that ethanolic
extract of J. montana considered as a potent choleretic agent
when given simultaneously with EE since it could produce
marked increase in serum cholesterol, bile acids and bilirubin
levels towards the normal values. Additionally, the extract
could also signiﬁcantly inhibit serum Pi-GST, c-GT, ALP
and ALT activity.
It is well known that NFKB is activated by a wide range of
agents and cytokines including TNF-a and IL-1a secreted
from the injured hepatic macrophages (Jaeschke et al., 2002).
TNF-a was reported to induce NO formation (Strater and
Moller, 1998). The increased NO production is recognized as
an important mediator of physiological and pathological pro-
cesses (Fox et al., 1997). As a result of these inﬂammatory and
destructive processes, the oxidative stress on the hepatic cells
was increased leading to the depletion of the antioxidant en-
zymes that scavenge the toxic superoxide and hydrogen perox-
ide radicals which promote lipid peroxidation (Dunger et al.,
1996). In the present study, the signiﬁcant increase in serum
32 M.A. Hussein, S.M. Abdel-Gawada-GST, NO and hepatic MDA with the concomitant decrease
in hepatic SOD, GPx and GR activity were detected after EE-
administration. These ﬁndings revealed the role of EE in
inducing oxidative stress on the hepatic tissue. This is because
the main function of SOD is represented in the removing of the
superoxide radical in order to prevent formation of hydroxyl
radical and the function of GPx is represented in its ability
to utilize and metabolize hydrogen peroxide in both cytosolic
and mitochondrial compartments (Gross and Wolin, 1995)
activity in EE-treated group is attributed to the sudden change
in the hepatocytes membrane permeability caused by the accu-
mulated bile acids in the liver (Orellana et al., 2000). The hepa-
toprotective effect on extract was demonstrated through
correcting the value of serum a-GST, NO and hepatic
MDA, SOD, GPx and GR that were signiﬁcant raised by
EE administration. This result indicated that ethanolic extract
of J. montana has a membrane stabilizing effect (Asai and
Miyazawa, 2001). Additionally, there is growing evidence that
the hepatoprotective effect of extract takes place directly at the
level of hepatocytes by lowering intracellular levels of choles-
terol and cytotoxic bile acids (Hochstein and Atallah, 1988).
Moreover, it has been reported that the ethanolic extract of
J. montana exert a cytoprotective effect by inducing liver glu-
tathione-s-transferase (Hussein, 2008). This antioxidant action
of extract is attributed to its ability to suppress many types of
transcription factors including hydrogen peroxide, tumor
necrosis factor-a.
As an indicator of oxidative stress, non-protein sulfhydryl
level was measured in the liver. The NP-SH concentration in
the liver tissue, decreased signiﬁcantly in the EE-treated rats,
while J. montana extract administration prevented the decre-
ment in NP-SH induced by EE. J. montana extract contributed
signiﬁcantly to the intracellular antioxidant defense system by
acting as a powerful consumer of singlet oxygen and hydroxyl
radicals. Obviously, the reduced level of NP-SH groups is due
to the involvement of reduced glutathione in rendering the
harmless estradiol metabolites by the formation of conjugates.
Treatment with the ethanolic extract of J. montana results in
stimulation of hepatic total, protein-bound and non-protein
sulfhydryl group’s biosynthesis. These results were agreement
by the ﬁnding of (Hussein, 2008) who demonstrated a signiﬁ-
cant increase in reduced glutathione by treatment with etha-
nolic extract of J. montana.
The preliminary phytochemical screening of ethanolic ex-
tract of J. montana, revealed the presence of ﬂavonoids. Flavo-
noids (or bioﬂavonoids) are natural products, they are capable
of modulating the activity of enzymes and affecting the behav-
ior of many cell systems and they possess signiﬁcant antihepa-
totoxic, antiallergic, antiinﬂammatory, antiosteoporotic, and
even antitumor and antioxidant activities (Carlo et al., 1991;
Rathee et al., 2006). High content of ﬂavonoids and phenolic
compounds was found in ethanolic extract, which may be
responsible for free radical activity.
Hepatoprotective effects of ethanolic extract of J. montana
against liver cholestasis induced by ethinylestradiol have not
been reported earlier to our knowledge, and this study is per-
haps the ﬁrst observation of its kind.
In conclusion, the present study showed that ethanolic
extract of J. montana has a powerful anticholestatic activity
against liver cholestasis induced by ethinylestradiol. In
addition, to its hepatoprotective, antioxidant action and free
radicals scavenging activity.References
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